2019 FDA TIDES (Peptides and Oligonucleotides) Harvest.
Al Shaer. Danah D; Al Musaimi. Othman O; Albericio. Fernando F; de la Torre. Beatriz G BG
Key Findings
- Seven peptide and oligonucleotide drugs received FDA approval in 2019, up from three the year before.
- Peptides are now being used not just as medicines but also as imaging agents, theragnostics, and parts of complex drugs like antibody‑drug conjugates.
- The review breaks down each approved TIDE by chemical structure, target, mechanism, and side‑effects.
Practical Outcomes
- For the biohacker community, the main takeaway is that the regulatory environment is becoming more friendly to peptide therapeutics, suggesting more options may become available soon. However, the article provides no direct dosing, safety, or protocol information for pt‑141, so it offers limited actionable guidance.
Summary
The 2019 FDA report shows that more peptide‑based drugs (called TIDES) were approved than in previous years, highlighting a growing trend for these molecules in medicine, but it doesn’t give any specific tips on how to use pt‑141 or other peptides.
Abstract
2019 has been an excellent year in terms of peptides and oligonucleotides (TIDES) approved by the FDA. Despite the drop in the number of total drugs approved by the FDA in 2019 in comparison with 2018 (48 vs. 59), the total number of TIDES authorized increased (seven vs. three). Year after year, TIDES are increasingly present in therapy, as imaging agents, theragnostic and constituent moieties of other complex drugs, such as antibody drug conjugates. This means a consolidation of these kinds of drugs in the pharmaceutical arena, paving the way in the coming years for the approval of others for diverse medical indications. Here the TIDES approved in 2019 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects.
Study Information
pubmed
2020
2020-03-05T00:00:00.000Z
10.3390/ph13030040
86
60